Cronos Extraction
About Cronos Extraction
Cronos Group's extraction division focuses on innovative cannabinoid research and processing, backed by Altria's strategic investment, with emphasis on biosynthetic cannabinoid production.
Key Facts
- 1Altria Group invested CAD $2.4 billion for a 45% stake, funding extraction technology R&D
- 2Partnered with Ginkgo Bioworks to develop fermentation-based production of rare cannabinoids
Latest News
CRON Drops as Cannabis Sector Faces Broad-Based Selling Pressure
Cronos Group shares decline alongside sector peers as cannabis stocks face headwinds from regulatory uncertainty and market volatility.
Cronos Stock Rally Faces Q1 Test as Cannabis Sector Volatility Persists
CRON shares climb ahead of earnings amid broader cannabis market uncertainty. Revenue trends and guidance will determine sustainability of recent gains.
Cronos Stock Shows Resilience as Cannabis Sector Faces Headwinds
CRON maintains stability on Nasdaq while broader cannabis market struggles with regulatory uncertainty and valuation pressures.
Cronos Group's Rally Faces Reality Check Amid Cannabis Sector Volatility
CRON stock momentum tested as cannabis industry grapples with regulatory uncertainty and competitive pressures in key markets.
Frequently Asked Questions
What is biosynthetic cannabinoid production?
Instead of extracting cannabinoids from plants, biosynthesis uses engineered yeast or bacteria to produce cannabinoids through fermentation, potentially at lower cost and higher purity.
Why did Altria invest in Cronos?
Altria, the tobacco giant behind Marlboro, invested in Cronos to gain exposure to the cannabis industry as a potential growth category amid declining cigarette sales.
More Cannabis Companies in Toronto
Products
- Cannabis Extracts
- Biosynthetic Cannabinoids
- Derivative Products
Specialties
Company Details
- Type
- Extraction
- Location
- Toronto, ON, Canada
- Founded
- 2012
- Publicly Traded
- Yes
- Ticker
- NASDAQ:CRON